Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 3/20 | 0.67 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.67 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.67 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7220679 | 1.00 | GNAI3 (0.67) | GNAI3GNAO1GNAI1SPHK1DRD2 | |
| Hydrochloric Acid SCHEMBL25362599 | 0.98 | GNAI3 (0.70) | GNAI3GNAO1GNAI1SPHK1DRD2 | |
| Propylamine SCHEMBL7227689 | 0.93 | GNAI3 (0.60) | GNAI3GNAO1GNAI1SPHK1DRD2 | |
| Dimethylamine SCHEMBL8113230 | 0.93 | GNAI3 (0.60) | GNAI3GNAO1GNAI1SPHK1DRD2 | |
| Dimethylamine SCHEMBL6939835 | 0.93 | GNAI3 (0.60) | GNAI3GNAO1GNAI1SPHK1DRD2 | |
| Diethylamine SCHEMBL6945135 | 0.89 | GNAI3 (0.56) | GNAI3GNAO1GNAI1SPHK1DRD2 | |
| SCHEMBL6941401 | 0.88 | GNAI3 (0.55) | GNAI3GNAO1GNAI1SPHK1DRD2 | |
| SCHEMBL6941884 | 0.86 | GNAO1 (0.81) | GNAI3GNAO1GNAI1SPHK1 | |
| SCHEMBL13102165 | 0.86 | — | — | |
| SCHEMBL13102164 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916759-A | Substituted quinazoline compound, preparation method, pharmaceutical composition and application thereof | 南京红云生物科技有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-115697996-A | Alkenyl pyrimidine compound, preparation method and application thereof | 南京红云生物科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-113717156-A | EGFR inhibitor, preparation method and application thereof | 南京红云生物科技有限公司 | 2021-11-30 | — | — | CN | claimed |
| EP-1451185-B1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2014-08-06 | — | — | EP | claimed |
| US-6906084-B2 | Indole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-06-14 | — | — | US | claimed |
| JP-2005514365-A | — | — | 2005-05-19 | — | — | JP | claimed |
| EP-1451185-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2004-09-01 | — | — | EP | claimed |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-10-23 | — | — | US | claimed |
| WO-2003044014-A1 | INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-30 | — | — | WO | claimed |
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4463452-B1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | ANIMA BIOTECH INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | ANIMA BIOTECH INC. (US) | 2025-04-03 | — | — | US | disclosed |
| EP-4463452-A2 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | Anima Biotech Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| WO-2000031063-A1 | SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-06-02 | — | — | WO | disclosed |
| WO-1999043675-A1 | 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES | AVENTIS PHARMACEUTICALS INC. (US) | 1999-09-02 | — | — | WO | disclosed |
| EP-0625507-B1 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO (JP) | 1997-07-23 | — | — | EP | disclosed |
| US-5621010-A | ANTIHYPERCHOLESTEROLEMIA AND ANTIATHEROSCLEROSIS | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0625507-A2 | Urea derivatives and their use as acat inhibitors | NISSHIN FLOUR MILLING CO., LTD. (JP) | 1994-11-23 | — | — | EP | disclosed |
| US-4153702-A | Basically alkylated dithiosalicyclic acid amides and their use as medicaments | BAYER AKTIENGESELLSCHAFT (DE) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344600-B2 | c-Myc mRNA translation modulators and uses thereof in the treatment of cancer | MYC, MYCBP, MYCBP2 | GNAI3 1100/4885GNAO1 2914/4885GNAI1 1396/4885 |
| US-20030199689-A1 | New indole derivatives as factor Xa inhibitors | F5, F12, F2 | GNAI3 1353/4885GNAO1 2313/4885GNAI1 1151/4885 |
| US-20250109128-A1 | C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER | MYC, MYCBP, MYCBP2 | GNAI3 1100/4885GNAO1 2914/4885GNAI1 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.